Skip to main content
SpringerLink
Log in

Nintedanib: First Global Approval

  • R&D Insight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Nintedanib (Ofev®) is an orally available, small, multiple receptor tyrosine kinase inhibitor developed by Boehringer Ingelheim for the treatment of idiopathic pulmonary fibrosis (IPF) and cancer. Nintedanib received its first global approval in the US in October 2014 for the treatment of IPF. Nintedanib has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the treatment of IPF, and for the second-line treatment in combination with docetaxel of locally advanced, metastatic or locally recurrent non-small cell lung cancer of adenocarcinoma tumour histology. Phase 3 development programmes are also underway for colorectal cancer and ovarian cancer. Phase 2 investigation is being conducted for a variety of other solid tumours, including hepatocellular carcinoma, mesothelioma, prostate cancer, glioblastoma, renal cell carcinoma and endometrial cancer. This article summarizes the milestones in the development of nintedanib leading to this first approval for IPF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol. 2011;163(1):141–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–61.

    Article  PubMed  Google Scholar 

  3. Woodcock HV, Molyneaux PL, Maher TM. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther. 2013;7:503–10.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. US FDA. FDA approves Ofev to treat idiopathic pulmonary fibrosis [media release]. 15 Oct 2014. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm418994.htm.

  5. US FDA. Ofev (nintedanib): US prescribing information 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf. Accessed 28 Oct.

  6. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.

    Article  CAS  PubMed  Google Scholar 

  7. Richeldi L, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87.

    Article  CAS  PubMed  Google Scholar 

  8. European Medicines Agency. Summary of opinion: Vargatef (nintedanib). 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002569/WC500173607.pdf. Accessed 28 Oct.

  9. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–82.

    Article  CAS  PubMed  Google Scholar 

  10. Cenik BK, Ostapoff KT, Gerber DE, et al. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther. 2013;12(6):992–1001.

    Article  PubMed Central  Google Scholar 

  11. Mesange P, Poindessous V, Sabbah M, et al. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget. 2014;5(13):4709–21.

    PubMed Central  PubMed  Google Scholar 

  12. Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349(2):209–20.

    Article  PubMed  Google Scholar 

  13. Herrmann F, Wollin L. Nintedanib prevents IL-1β-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors [abstract no. P3501]. In: European Respiratory Society Congress, Munich; 6–10 Sep 2014.

  14. Hostettler K, Papakonstantinou E, Zhong J, et al. Nintedanib (BIBF 1120) prevents TGF-β-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis [abstract no. P746]. In: European Respiratory Society Congress, Munich; 6–10 Sep 2014.

  15. Mross K, Buchert M, Frost A, et al. Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. BMC Cancer. 2014;14:510.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Eisen T, Shparyk Y, Macleod N, et al. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Invest New Drugs. 2013;31(5):1283–93.

    Article  CAS  PubMed  Google Scholar 

  17. Freiwald M, Liesenfeld K, Bruno R, et al. A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small-cell lung cancer [abstract no. 14528]. In: 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL; 30 May–3 Jun 2008.

  18. Stopfer P, Kaiser R, Snelder N. A population pharmacokinetic model for BIBF 1120, a triple angiokinase inhibitor, in cancer patients after single and multiple oral dosing [abstract no. 96]. EJC 2006;Supp 4(12):33.

  19. Hanna NH, Zhao Y, Kaiser R, et al. Pharmacokinetic analysis of a phase I trial investigating continuous treatment with the angiokinase inhibitor BIBF 1120 combined with pemetrexed in previously treated patients with non-small cell lung cancer [abstract no. 14511]. In: 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL; 30 May–3 Jun 2008.

  20. Stopfer P, Rathgen K, Liesener A. Pharmacokinetics of BIBF 1120 after administration of single doses of 100 mg [14C]-BIBF 1120 [abstract no. 478P]. Ann Oncol. 2008;19(Supp 8):8158.

  21. Camidge DR, Conkling P, Stephenson JJ, et al. Pharmacokientic analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer [abstract no. 3567]. J Clin Oncol. 2008;26(15S).

  22. Raymond E, Goldwasser F, Bousquet G, et al. A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients [abstract no. 704]. EJC 2007;Suppl 5(108).

  23. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–55.

    Article  CAS  PubMed  Google Scholar 

  24. Hanna NH, Kaiser R, Sullivan RN, et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy [abstract no. 8034]. In: 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL; 31 May–4 Jun 2013.

  25. Hanna N, Kaiser R, Kim JH, et al. Retrospective evaluation of the futility analysis in LUME Lung 2, a randomized, double-blind, placebo-controlled phase 3 trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first line chemotherapy [abstract no. P327/3418]. In: European Cancer Congress, Amsterdam; 27 Sep–1 Oct 2013.

  26. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011;22:1374–81.

    Article  CAS  PubMed  Google Scholar 

  27. Okamoto I, Miyazaki M, Takeda M, et al. The tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. J Thorac Oncol. 2014. doi:10.1097/jto.0000000000000395.

  28. Ellis PM, Kaiser R, Zhao Y, et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res. 2010. doi:10.1158/1078-0432.CCR-09-2944.

  29. Daga H, Takeda K, Okada H, et al. Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): a phase I study [abstract no. 8056]. J Clin Oncol. 2013;31(15 Suppl 1).

  30. Du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/− nintedanib for advanced ovarian cancer. Int J Gynecol Cancer. 2013;1(8 Suppl 1):7–8.

    Google Scholar 

  31. Kristensen G, Harter P, Treden O, et al. Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC) [abstract no. 5556]. In: 50th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL; 30 May–3 Jun 2014.

  32. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29(28):3798–803.

    Article  CAS  PubMed  Google Scholar 

  33. De Leon MC, Arnold A, Rossi EC, et al. Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149 [abstract no. 5541]. J Clin Oncol. 2014;32(15 Suppl 1).

  34. Bouche O, Maindrault-Goebel F, Ducreux M, et al. Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res. 2011;31(6):2271–81.

    CAS  PubMed  Google Scholar 

  35. Van Cutsem E, Prenen H, Guillen-Ponce C, et al. A phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer [abstract no. 14LBA]. In: European Multidisciplinary Cancer Congress, Stockholm; 23–27 Sep 2011.

  36. Eisen T, Shparyk Y, Jones R, et al. Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients [abstract no. 4506]. In: 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL; 31 May–4 Jun 2013.

  37. Yen C, Kim TY, Feng YH, et al. Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): a randomised phase II trial [abstract no. P408/2580]. In: European Cancer Congress, Amsterdam; 27 Sep–1 Oct 2013.

  38. Palmer DH, Peck-Radosavljevic M, Ma YT, et al. Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC) [abstract no. TPS4160]. In: 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL; 31 May–4 Jun 2013.

  39. Droz J-P, Medioni J, Chevreau C, et al. Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel. Anticancer Drugs. 2014;25(9):1081–8.

    Article  CAS  PubMed  Google Scholar 

  40. Molife LR, Omlin A, Jones RJ, et al. Randomized phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol. 2014;10(2):219–31.

    Article  CAS  PubMed  Google Scholar 

  41. Bousquet G, Alexandre J, Le Tourneau C, et al. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer. 2011;105(11):1640–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Dizon DS, Sill MW, Schilder JM, et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2014. doi:10.1016/j.ygyno.2014.10.001.

  43. Lassen U, Mau-Soerensen M, Muhic A. Phase II study of BIBF1120 in recurrent glioblastoma multiforme [abstract no. 3701]. In: 103rd Annual Meeting of the American Association for Cancer Research, Chicago, IL; 31 Mar–4 Apr 2012.

  44. Norden AD, Schiff D, Ahluwalia MS, et al. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: final results [abstract no. 2053]. J Clin Oncol. 2014;32(15 Suppl 1).

  45. Muhic A, Poulsen HS, Sorensen M, et al. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol. 2013;111(2):205–12.

    Article  CAS  PubMed  Google Scholar 

  46. Scagliotti GV, Leighl NB, Nowak AK, et al. Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): an international, multicenter, randomized, double-blind, placebo-controlled phase II study [abstract no. TPS7612]. J Clin Oncol. 2014;32(15 Suppl 1).

  47. Kropff M, Kienast J, Bisping G, et al. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. Anticancer Res. 2009;29:4233–8.

    CAS  PubMed  Google Scholar 

  48. Quintela-Fandino M, Urruticoechea A, Guerra J, et al. Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). Br J Cancer. 2014;111(6):1060–4.

    Article  CAS  PubMed  Google Scholar 

  49. Du Bois A, Huober J, Stopfer P, et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol. 2010;21(2):370–5.

    Article  PubMed  Google Scholar 

  50. Krug U, Knoblauch N, Gerss J, et al. Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment. J Clin Oncol. 2014;32(15 Suppl 1).

  51. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16(1):311–9.

    Article  CAS  PubMed  Google Scholar 

  52. Lee CP, Taylor NJ, Attard G, et al. A phase I study of BIBF 1120 an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging [abstract no. 3015]. J Clin Oncol. 2006;24(18 Suppl).

  53. Lee CP, Attard G, Poupard L, et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies [abstract no. 3054]. J Clin Oncol. 2005;23(16 Suppl).

  54. Okamoto I, Kaneda H, Satoh T, et al. Phase I clinical and biomarker study of BIBF 1120, an oral multitarget tyrosine kinase inhibitor, in patients with advanced solid tumors: impact of CD133 and CD117-positive cells on a biomarker of an antiangiogenic inhibitor [abstract no. 3572]. J Clin Oncol. 2009;27(15 Suppl).

  55. Scheffler M, Gardizi M, Bos M, et al. BARIS: a phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination [abstract no. P1.11-043]. In: 15th World Conference on Lung Cancer, Sydney, NSW; 27–31 Oct 2013.

  56. Kaneda H, Okamoto I, Satoh T, et al. Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors [abstract no. P-1243]. In: 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology, Berlin; 20–24 Sep 2009.

  57. De Braud FG, Cascinu S, Spitaleri G, et al. A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors [abstract no. 2556]. J Clin Oncol. 2013;31(15 Suppl 1).

  58. Reck M, Mellemgaard A, Orlov SV, et al. Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D) [abstract no. 8100]. In: 50th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL; 30 May–3 Jun 2014.

  59. Boehringer Ingelheim, National Comprehensive Cancer Network. Four researchers awarded grants to investigate effectiveness of nintedanib* in lung, colorectal, and gastrointestinal cancers [media release]. 24 Sep 2014. http://www.nccn.org/about/news/newsinfo.aspx?NewsID=450.

  60. Boehringer Ingelheim. Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis [media release]. 16 Oct 2014. http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/16_october_2014.html.

Download references

Disclosure

The preparation of this report was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. P. L. McCormack is a salaried employee of Adis, Springer SBM.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Paul L. McCormack

Authors
  1. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul L. McCormack.

Additional information

This profile has been extracted and modified from the Adis R&D Insight drug pipeline database. Adis R&D Insight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCormack, P.L. Nintedanib: First Global Approval. Drugs 75, 129–139 (2015). https://doi.org/10.1007/s40265-014-0335-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0335-0

Keywords

Search

Navigation